Published in Medical Letter on the CDC and FDA, December 31st, 2006
Cudkowicz and Shefner are co-principal study investigators of the trial.
A poster presentation titled "A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALS" was available and Cudkowicz delivered a 15-minute closing slide presentation on the same topic.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA